Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Scott P. Henry"'
Autor:
Wesley Partridge, Sebastien A. Burel, Annie Ferng, Shuting Xia, T. Jesse Kwoh, Scott P. Henry, Brenda F. Baker
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 4, Pp 575-580 (2023)
Abstract This analysis sought to assess the clinical predictivity of an in vitro assay which utilized the human B‐lymphoma BJAB cell line, for identification of antisense oligonucleotides (ASOs) with the potential to elicit innate immune activation
Externí odkaz:
https://doaj.org/article/c6738881c87b44a086e9231dab0c5d37
Autor:
Martina H. Lundberg Slingsby, Prakrith Vijey, I-Ting Tsai, Harvey Roweth, Genevieve Couldwell, Adrian R. Wilkie, Hans Gaus, Jazana M. Goolsby, Ross Okazaki, Brooke E. Terkovich, John W. Semple, Jonathan N. Thon, Scott P. Henry, Padmakumar Narayanan, Joseph E. Italiano Jr.
Publikováno v:
Haematologica, Vol 107, Iss 2 (2021)
Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes. Phenotype 1 is a moderate (b
Externí odkaz:
https://doaj.org/article/ac735069e61e406db2676efc4ab4c007
Autor:
Colby S. Shemesh, Rosie Z. Yu, Mark S. Warren, Michael Liu, Mirza Jahic, Brandon Nichols, Noah Post, Song Lin, Daniel A. Norris, Eunju Hurh, Jane Huang, Tanya Watanabe, Scott P. Henry, Yanfeng Wang
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 9, Iss C, Pp 34-47 (2017)
Antisense oligonucleotides are metabolized by nucleases and drug interactions with small drug molecules at either the cytochrome P450 (CYP) enzyme or transporter levels have not been observed to date. Herein, a comprehensive in vitro assessment of th
Externí odkaz:
https://doaj.org/article/e207d7ae85c046919a7c54818f631e90
Autor:
Alexander J. Szalai, Mark A. McCrory, Dongqi Xing, Fadi G. Hage, Andrew Miller, Suzanne Oparil, Yiu-Fai Chen, Michelle Mazzone, Richard Early, Scott P. Henry, Thomas A. Zanardi, Mark J. Graham, Rosanne M. Crooke
Publikováno v:
Mediators of Inflammation, Vol 2014 (2014)
Raised blood C-reactive protein (CRP) level is a predictor of cardiovascular events, but whether blood CRP is causal in the disease process is unknown. The latter would best be defined by pharmacological inhibition of the protein in the context of a
Externí odkaz:
https://doaj.org/article/1353b401cb894bb4a6035781bd29725d
Autor:
Wesley Partridge, Sebastien A. Burel, Annie Ferng, Shuting Xia, T. Jesse Kwoh, Scott P. Henry, Brenda F. Baker
Publikováno v:
Clinical and Translational Science. 16:575-580
Autor:
Lijiang Shen, Andrea Wong, Satoru Oneda, Brian R. Curtis, Joe Schroeder, Tom Zanardi, Jeffery A. Engelhardt, Scott P. Henry, Padmakumar Narayanan
Publikováno v:
Nucleic Acid Therapeutics.
Autor:
Adam J. Pollak, Patrick Cauntay, Todd Machemer, Suzanne Paz, Sagar Damle, Scott P. Henry, Sebastien A. Burel
Publikováno v:
Nucleic acid therapeutics. 32(6)
Nucleic acid-based phosphorothioate containing antisense oligonucleotides (PS-ASOs) have the potential to activate cellular innate immune responses, and the level of activation can vary quite dramatically with sequence. Minimizing the degree of proin
Autor:
Sebastien A. Burel, Todd Machemer, Brenda F. Baker, T. Jesse Kwoh, Suzanne Paz, Husam Younis, Scott P. Henry
Publikováno v:
Nucleic acid therapeutics. 32(6)
A human peripheral blood mononuclear cell (PBMC)-based assay was developed to identify antisense oligonucleotide (ASO) with the potential to activate a cellular innate immune response outside of an acceptable level. The development of this assay was
Autor:
Shuling Guo, Birgit Korbmacher, Jeffrey A Engelhardt, Mariam Aghajan, Laura Boone, Thomas A. Zanardi, Scott P. Henry, Sebastien A. Burel, Bobby Prill, Yanfeng Wang
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 377:51-63
Cellular uptake of antisense oligonucleotides (ASOs) is one of the main determinants of in vivo activity and potency. A significant advancement in improving uptake into cells has come through the conjugation of ASOs to triantenarry N-acetyl-galactosa
Autor:
Yanfeng Wang, Padma Narayanan, Daniel A. Norris, Richard S. Geary, Scott P. Henry, Tae-Won Kim, Brett P. Monia, Rosie Z. Yu
Publikováno v:
Nucleic Acid Therapeutics. 30:265-275
Inotersen (TEGSEDI™) is a 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide, intended for treating hereditary transthyretin (TTR) amyloidosis with polyneuropathy. The potential immunogenicity (IM) response to inotersen was evaluated in chron